Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 195 Neoplasm Metastasis 22 Prostatic Neoplasms, Castration-Resistant 20 Breast Neoplasms 19 Neoplasms 18 Metastatic Castration Resistant Prostate Cancer 10 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Triple Negative Breast Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Pancreatic Neoplasms 5 Colorectal Neoplasms 5 Castration-resistant Prostate Cancer 5 Carcinoma, Non-Small-Cell Lung 5 Melanoma 4 Carcinoma, Hepatocellular 4 Bulbo-Spinal Atrophy, X-Linked 4 Adenocarcinoma 4 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Prostate Adenocarcinoma 3 Ovarian Neoplasms 3 Carcinoma, Renal Cell 3 mCRPC 2 Uterine Cervical Neoplasms 2 Recurrence 2 Prostatic Diseases 2 Non-metastatic Castration-resistant Prostate Cancer 2

Interventions

exemestane 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Primary Breast Cancer ER+ve × enzalutamide × Clear all

NCT02676986 2024-07-05

ARB

Queen Mary University of London

Phase 2 Completed

Primary Breast Cancer ER+ve

Data powered by HemOnc (CC BY 4.0) Colophon ⚡